{
    "clinical_study": {
        "@rank": "58735", 
        "arm_group": {
            "arm_group_label": "Treatment (cabozantinib-s-malate)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well cabozantinib-s-malate works in treating patients with\n      recurrent or metastatic endometrial cancer. Cabozantinib-s-malate may stop the growth of\n      tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood\n      flow to the tumor."
        }, 
        "brief_title": "Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer", 
        "condition": [
            "Endometrial Adenosquamous Cell Carcinoma", 
            "Endometrial Clear Cell Carcinoma", 
            "Endometrial Papillary Serous Carcinoma", 
            "Recurrent Endometrial Carcinoma", 
            "Stage IVA Endometrial Carcinoma", 
            "Stage IVB Endometrial Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Endometrial Neoplasms", 
                "Carcinoma, Adenosquamous", 
                "Adenocarcinoma, Clear Cell", 
                "Adenomyoepithelioma", 
                "Cystadenocarcinoma, Serous"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Determine efficacy of single agent cabozantinib in women previously receiving one line of\n      chemotherapy for metastatic endometrial cancer or with progression within 12 months of\n      completing adjuvant therapy, with co-primary endpoints of objective response rate by\n      Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and progression-free-survival at\n      12 weeks (PFS).\n\n      SECONDARY OBJECTIVES:\n\n      I. Correlation of clinical response with: baseline molecular status of archival tumor\n      (hepatocyte growth factor receptor [c-met] amplification & mutation status).\n\n      OUTLINE:\n\n      Patients receive cabozantinib-s-malate orally (PO) once daily (QD) on days 1-28. Courses\n      repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up every 4 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically or cytologically confirmed metastatic endometrial\n             cancer; eligible histologies for the experimental cohort are: endometrioid, serous or\n             mixed; eligible histologies for the exploratory cohort are: carcinosarcoma, clear\n             cell or adenosquamous\n\n          -  Patients must have measurable disease, defined as at least one lesion that can be\n             accurately measured in at least one dimension (longest diameter to be recorded for\n             non-nodal lesions and short axis for nodal lesions) as > 10 mm with computed\n             tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam;\n             patients must have radiographic evidence of disease progression following the most\n             recent line of treatment\n\n          -  Prior therapy: Eligible subjects must have had 1 line of systemic cytotoxic\n             treatment; this may be adjuvant therapy with documented progression within 12 months\n             of completion, or 1 line of cytotoxic therapy for metastatic disease; prior hormonal\n             therapy for metastatic/recurrent disease is also allowed; prior targeted therapy not\n             directed against cMET or vascular endothelial growth factor (VEGF) pathways is\n             allowed\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\n\n          -  Life expectancy of greater than 3 months\n\n          -  Absolute neutrophil count >= 1.5 x 10^9/L\n\n          -  Platelets >= 100 x 10^9/L\n\n          -  Total bilirubin =< 1.5 x upper limit of normal (ULN)\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 3.0 X institutional upper limit of normal\n\n          -  Creatinine =< 1.5 x ULN OR creatinine clearance >= 50 mL/min/1.73 m^2 for patients\n             with creatinine levels above institutional normal\n\n          -  Hemoglobin >= 90g/L\n\n          -  Serum albumin >= 28 g/L\n\n          -  Lipase < 2.0 x ULN; no radiologic or clinical evidence of pancreatitis\n\n          -  Urine protein/creatinine ratio (UPCR) =< 1\n\n          -  Serum phosphorus, calcium, magnesium and potassium >= lower limit of normal (LLN)\n\n          -  Women of childbearing potential must have a negative pregnancy test at screening;\n             women of childbearing potential include women who have experienced menarche and who\n             have not undergone successful surgical sterilization (hysterectomy, bilateral tubal\n             ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopausal is\n             defined as amenorrhea >= 12 consecutive months; note: women who have been amenorrheic\n             for 12 or more months are still considered to be of childbearing potential if the\n             amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression\n             or any other reversible reason\n\n          -  Women of child-bearing potential must agree to use adequate contraception prior to\n             study entry and for the duration of study participation; should a woman become\n             pregnant or suspect she is pregnant while she is participating in this study, she\n             should inform her treating physician immediately; sexually active subjects must agree\n             to use medically accepted barrier methods of contraception (e.g., male or female\n             condom) during the course of the study and for 4 months after the last dose of study\n             drug(s), even if oral contraceptives are also used; all subjects of reproductive\n             potential must agree to use both a barrier method and a second method of birth\n             control during the course of the study and for 4 months after the last dose of study\n             drug(s)\n\n          -  Patients must consent to analysis on archival tissue; if archival sample is not\n             available, a sufficient tumor biopsy can be performed a minimum of 28 days prior to\n             start of treatment if felt to be clinically reasonable\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for\n             nitrosoureas or mitomycin C) prior to entering the study or those who have not\n             recovered from adverse events due to agents administered more than 4 weeks earlier\n\n          -  The subject has received cytotoxic chemotherapy (including investigational cytotoxic\n             chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or\n             nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment\n\n          -  Prior treatment with cabozantinib\n\n          -  The subject has received radiation therapy:\n\n               -  To the thoracic cavity, abdomen, or pelvis within 3 months before the first dose\n                  of study treatment, or has ongoing complications, or is without complete\n                  recovery and healing from prior radiation therapy\n\n               -  To bone metastasis within 14 days before the first dose of study treatment\n\n               -  To any other site(s) within 28 days before the first dose of study treatment\n\n          -  The subject has received radionuclide treatment within 6 weeks of the first dose of\n             study treatment\n\n          -  The subject has received prior treatment with a small molecule kinase inhibitor or a\n             hormonal therapy (including investigational kinase inhibitors or hormones) within 14\n             days or five half-lives of the compound or active metabolites, whichever is longer,\n             before the first dose of study treatment\n\n          -  The subject has received any other type of investigational agent within 28 days\n             before the first dose of study treatment\n\n          -  The subject has not recovered to baseline or Common Terminology Criteria for Adverse\n             Events (CTCAE) =< grade 1 from related toxicity to all prior therapies except\n             alopecia and other non-clinically significant adverse events (AEs)\n\n          -  Any other prior malignancy from which the patient has been disease free for less than\n             3 years, with the exception of adequately treated and cured basal or squamous cell\n             skin cancer, superficial bladder cancer, carcinoma in situ of any site or any other\n             cancer\n\n          -  Patients with known brain metastases should be excluded from this clinical trial\n\n          -  The subject has prothrombin time (PT)/international normalized ratio (INR) or partial\n             thromboplastin time (PTT) test >= 1.3 x the laboratory ULN within 7 days before the\n             first dose of study treatment\n\n          -  The subject requires concomitant treatment, in therapeutic doses, with anticoagulants\n             such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa\n             inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81\n             mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight\n             heparin (LMWH) are permitted\n\n          -  The subject requires chronic concomitant treatment of strong cytochrome P450 (CYP)3A4\n             inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin,\n             rifapentine, phenobarbital, and St. John's Wort)\n\n          -  The subject has experienced any of the following:\n\n               -  Clinically-significant gastrointestinal bleeding within 6 months before the\n                  first dose of study treatment\n\n               -  Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the\n                  first dose of study treatment\n\n               -  Any other signs indicative of pulmonary hemorrhage within 3 months before the\n                  first dose of study treatment\n\n          -  The subject has radiographic evidence of cavitating pulmonary lesion(s)\n\n          -  The subject has tumor in contact with, invading or encasing any major blood vessels\n\n          -  The subject has evidence of tumor invading the gastrointestinal (GI) tract\n             (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of\n             endotracheal or endobronchial tumor within 28 days before the first dose of\n             cabozantinib\n\n          -  The subject has uncontrolled, significant intercurrent or recent illness including,\n             but not limited to, the following conditions:\n\n               -  Cardiovascular disorders including:\n\n                    -  Congestive heart failure (CHF): New York Heart Association (NYHA) class III\n                       (moderate) or class IV (severe) at the time of screening\n\n                    -  Concurrent uncontrolled hypertension defined as sustained blood pressure\n                       (BP) > 140 mmHg systolic, or > 90 mmHg diastolic despite optimal\n                       antihypertensive treatment within 7 days of the first dose of study\n                       treatment\n\n                    -  Any history of congenital long QT syndrome\n\n                    -  Any of the following within 6 months before the first dose of study\n                       treatment:\n\n                         -  Unstable angina pectoris\n\n                         -  Clinically-significant cardiac arrhythmias\n\n                         -  Stroke (including transient ischemic attack [TIA], or other ischemic\n                            event)\n\n                         -  Myocardial infarction\n\n                         -  Thromboembolic event requiring therapeutic anticoagulation; (Note:\n                            subjects with a venous filter [e.g. vena cava filter] are not eligible\n                            for this study)\n\n          -  Gastrointestinal disorders particularly those associated with a high risk of\n             perforation or fistula formation including:\n\n               -  Any of the following within 28 days before the first dose of study treatment\n\n                    -  Intra-abdominal tumor/metastases invading GI mucosa\n\n                    -  Active peptic ulcer disease,\n\n                    -  Inflammatory bowel disease (including ulcerative colitis and Crohn's\n                       disease), diverticulitis, cholecystitis, symptomatic cholangitis or\n                       appendicitis\n\n                    -  Malabsorption syndrome\n\n               -  Any of the following within 6 months before the first dose of study treatment:\n\n                    -  Abdominal fistula\n\n                    -  Gastrointestinal perforation\n\n                    -  Bowel obstruction or gastric outlet obstruction\n\n                    -  Intra-abdominal abscess; Note: Complete resolution of an intra-abdominal\n                       abscess must be confirmed prior to initiating treatment with cabozantinib\n                       even if the abscess occurred more than 6 months before the first dose of\n                       study treatment\n\n          -  Other disorders associated with a high risk of fistula formation including\n             percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before the\n             first dose of study therapy\n\n          -  Other clinically significant disorders such as:\n\n               -  Active infection requiring systemic treatment within 28 days before the first\n                  dose of study treatment\n\n               -  Serious non-healing wound/ulcer/bone fracture within 28 days before the first\n                  dose of study treatment\n\n               -  History of organ transplant\n\n               -  Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days\n                  before the first dose of study treatment\n\n               -  History of major surgery as follows:\n\n                    -  Major surgery within 3 months of the first dose of cabozantinib if there\n                       were no wound healing complications or within 6 months of the first dose of\n                       cabozantinib if there were wound complications\n\n                    -  Minor surgery within 1 month of the first dose of cabozantinib if there\n                       were no wound healing complications or within 3 months of the first dose of\n                       cabozantinib if there were wound complications\n\n                         -  In addition, complete wound healing from prior surgery must be\n                            confirmed at least 28 days before the first dose of cabozantinib\n                            irrespective of the time from surgery\n\n          -  The subject is unable to swallow tablets\n\n          -  The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) >\n             500 ms within 28 days before randomization; Note: if initial QTcF is found to be >\n             500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes\n             should be performed; if the average of these three consecutive results for QTcF is =<\n             500 ms, the subject meets eligibility in this regard\n\n          -  The subject is unable or unwilling to abide by the study protocol or cooperate fully\n             with the investigator or designee\n\n          -  The subject has had evidence within 2 years of the start of study treatment of\n             another malignancy which required systemic treatment\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to XL184\n\n          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if\n             the mother is treated with XL184\n\n          -  Known human immunodeficiency virus (HIV)-positive patients on combination\n             antiretroviral therapy are ineligible"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01815151", 
            "nct_id": "NCT01935934", 
            "org_study_id": "NCI-2013-00890", 
            "secondary_id": [
                "NCI-2013-00890", 
                "PHL-086", 
                "9322", 
                "N01CM00032"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (cabozantinib-s-malate)", 
                "description": "Given PO", 
                "intervention_name": "cabozantinib-s-malate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BMS-907351", 
                    "Cometriq", 
                    "XL184"
                ]
            }, 
            {
                "arm_group_label": "Treatment (cabozantinib-s-malate)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (cabozantinib-s-malate)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mcristea@coh.org", 
                    "last_name": "Mihaela C. Cristea", 
                    "phone": "626-256-4673"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Mihaela C. Cristea", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lroman@usc.edu", 
                    "last_name": "Lynda D. Roman", 
                    "phone": "323-226-3405"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC Norris Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Lynda D. Roman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Skoehler@cohmg.com", 
                    "last_name": "Stephen C. Koehler", 
                    "phone": "626-396-2900"
                }, 
                "facility": {
                    "address": {
                        "city": "Pasadena", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91105"
                    }, 
                    "name": "City of Hope Medical Group Inc"
                }, 
                "investigator": {
                    "last_name": "Stephen C. Koehler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sidney.scudder@ucdmc.ucdavis.edu", 
                    "last_name": "Sidney A. Scudder", 
                    "phone": "916-734-3772"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California at Davis Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Sidney A. Scudder", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gfleming@medicine.bsd.uchicago.edu", 
                    "last_name": "Gini F. Fleming", 
                    "phone": "773-702-6712"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago"
                }, 
                "investigator": {
                    "last_name": "Gini F. Fleming", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "JLWADE3@sbcglobal.net", 
                    "last_name": "James L. Wade", 
                    "phone": "217-876-6600"
                }, 
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62526"
                    }, 
                    "name": "Decatur Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "James L. Wade", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jhurteau@uchicago.edu", 
                    "last_name": "Jean A. Hurteau", 
                    "phone": "847-570-2639"
                }, 
                "facility": {
                    "address": {
                        "city": "Evanston", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60201"
                    }, 
                    "name": "NorthShore University HealthSystem-Evanston Hospital"
                }, 
                "investigator": {
                    "last_name": "Jean A. Hurteau", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dmatei@iu.edu", 
                    "last_name": "Daniela E. Matei", 
                    "phone": "317-278-0070"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Daniela E. Matei", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ronaldbu@umich.edu", 
                    "last_name": "Ronald J. Buckanovich", 
                    "phone": "734-764-2395"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan"
                }, 
                "investigator": {
                    "last_name": "Ronald J. Buckanovich", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rmorris@med.wayne.edu", 
                    "last_name": "Robert T. Morris", 
                    "phone": "313-576-9435"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Wayne State University/Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Robert T. Morris", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lainie.Martin@fccc.edu", 
                    "last_name": "Lainie P. Martin", 
                    "phone": "215-728-3889"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Lainie P. Martin", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "edwarp@mail.magee.edu", 
                    "last_name": "Robert P. Edwards", 
                    "phone": "412-641-5418"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Magee-Womens Hospital of UPMC"
                }, 
                "investigator": {
                    "last_name": "Robert P. Edwards", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "helen.steed@albertahealthservices.ca", 
                    "last_name": "Helen L. Steed", 
                    "phone": "780-432-8560"
                }, 
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 1Z2"
                    }, 
                    "name": "Cross Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Helen L. Steed", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "amit.oza@uhn.ca", 
                    "last_name": "Amit M. Oza", 
                    "phone": "416-946-2818"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }, 
                    "name": "BCCA-Vancouver Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Amit M. Oza", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Hal.hirte@jcc.hhsc.ca", 
                    "last_name": "Holger W. Hirte", 
                    "phone": "905-387-9495"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "Juravinski Cancer Centre at Hamilton Health Sciences"
                }, 
                "investigator": {
                    "last_name": "Holger W. Hirte", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jim.biagi@krcc.on.ca", 
                    "last_name": "James J. Biagi", 
                    "phone": "613-544-2630"
                }, 
                "facility": {
                    "address": {
                        "city": "Kingston", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K7L 5P9"
                    }, 
                    "name": "Cancer Centre of Southeastern Ontario at Kingston General Hospital"
                }, 
                "investigator": {
                    "last_name": "James J. Biagi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Stephen.welch@lhsc.on.ca", 
                    "last_name": "Stephen A. Welch", 
                    "phone": "519-685-8640"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4L6"
                    }, 
                    "name": "London Regional Cancer Program"
                }, 
                "investigator": {
                    "last_name": "Stephen A. Welch", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jwebserpals@ottawahospital.on.ca", 
                    "last_name": "Johanne I. Weberpals", 
                    "phone": "613-737-8899"
                }, 
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L6"
                    }, 
                    "name": "Ottawa General Hospital"
                }, 
                "investigator": {
                    "last_name": "Johanne I. Weberpals", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "amit.oza@uhn.ca", 
                    "last_name": "Amit M. Oza", 
                    "phone": "416-946-2818"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "University Health Network-Princess Margaret Hospital"
                }, 
                "investigator": {
                    "last_name": "Amit M. Oza", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer", 
        "overall_official": {
            "affiliation": "University Health Network-Princess Margaret Hospital", 
            "last_name": "Amit Oza", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Response rate (RR) using RECIST version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks post-treatment"
            }, 
            {
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Time from start of treatment to time of progression or death, assessed at 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935934"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Baseline molecular status of archival tumor (c-met amplification & mutation status)", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Pharmacodynamic responses in levels of soluble, circulating angiogenic factors", 
                "safety_issue": "No", 
                "time_frame": "Baseline and day 1 of course 2"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}